2. >>Archive

ASCRS: A Look Ahead in Eye Surgery

At this year's American Society of Cataract and Refractive Surgery symposium, enthusiasm over technological advances in nearly every product segment, including presbyopia-correcting IOLs and cataract surgeries, was dampened by the reality of the softening demand for laser vision correction.

by Michael Lachman

The American Society of Cataract and Refractive Surgery (ASCRS) held its annual symposium in Chicago in April, with record attendance driven by a strong international showing. Enthusiasm over technological advances in nearly every product segment was dampened by the reality of softening demand for laser vision correction (LVC) in the US in 2008 due to the slowing economy. An additional cause for concern in the domestic LVC market is negative publicity arising from the April 25 Food & Drug Administration (FDA) panel meeting to review the safety of laser-assisted in situ keratomileusis (LASIK), the dominant LVC procedure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Does Makary’s Reorg Choice Mark FDA Turning Point?

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

New Treatment For Chronic Facial Pain Could Launch By Fall 2025

 
• By Elizabeth Orr

NeuroOne is preparing to submit its OneRF Trigeminal Nerve Ablation System to the US FDA for treating trigeminal neuralgia, a chronic facial pain condition. CEO Dave Rosa told Medtech Insight that he expects a possible product launch by fall 2025.